Glaucoma News
-
5 Ways OCT Technology Can Benefit Your Practice
The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. But when it comes to detecting severe conditions like glaucoma and macular degeneration, the naked eye’s powers are limited. That’s where OCT technology comes in handy. OCTs have become a standard of care that every practice ...
-
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada (`NSERC`) Alliance Grant Funding
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. Kumar from University of British Columbia (UBC) VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals ...
-
iSTAR Medical appoints leading glaucoma specialist Prof. Kaweh Mansouri as Chief Medical Officer
WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO). Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, ...
-
MediPrint™ Ophthalmics Announces Acceptance and Presentation of Poster at the Upcoming GSLS in Las Vegas
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results ...
-
AbbVie and iSTAR Medical Announce Strategic Alliance for the Treatment of Glaucoma
NORTH CHICAGO, Ill. and WAVRE, BELGIUM, July 20, 2022 – AbbVie (NYSE: ABBV) and iSTAR Medical SA, today announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject® device, a next-generation minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. This complementary alliance will support iSTAR Medical’s development ...
-
Prof. Dr med. Marc Schargus presents a pooled meta-analysis on MINIject at DOC 2022
A meta-analysis from the STAR-I, STAR-II and STAR-III trials on MINIject® was presented at the 34th International Congress of German Ophthalmic Surgeons (DOC) by Prof. Dr med. Marc Schargus (Asklepios Klinik Nord, Hamburg). It was entitled, “Patients with Open Angle Glaucoma Who Consistently Achieve Low Intraocular Pressures (≤18 mmHg) up to Two-years after Implantation with ...
-
iSTAR Medical to attend the 34th International Congress of German Ophthalmic Surgeons (DOC)
We will be in Nuremberg next week at the DOC congress where Prof. Dr med. Marc Schargus (Asklepios Klinik Nord, Hamburg) will be presenting a meta-analysis from the STAR-I, STAR-II and STAR-III trials on patients with open-angle glaucoma who consistently achieve low diurnal intraocular pressures (IOP) of ≤18 mmHg up to two-years after implantation with MINIject. The Advanced Glaucoma ...
-
What Are D-Glucosamines?
Glucosamine is a natural component of cartilage and is widely used as an over-the-counter nutritional supplement to reduce the pain and cartilage loss of osteoarthritis. Glucosamine is usually taken in combination with chondroitin, which is a glycosaminoglycan that also exists in cartilage.Glucosamine is an amino sugar and an important molecule in the biochemical pathway of glycosylated protein ...
-
iSTAR Medical Presents Positive Consistent Results for MINIject Across Three International Glaucoma Trials
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
-
Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Datagrafic lines 4 Sight Sciences’ OMNI® Surgical System Redu
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced publication in Clinical Ophthalmology of its 12-month outcomes in the GEMINI study, including results from a Hispanic population subset. The final study results demonstrated that canaloplasty ...
-
Eyevensys Recaps Highlights from Investigator Meeting and Presentations at the ARVO 2022 Annual Conference
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference held in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in ...
By Eyevensys
-
Sight Sciences Reports First Quarter 2022 Financial Resultsgrafic lines 4 Sight S
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the quarter ended March 31, 2022. Recent Business Highlights Generated first quarter 2022 total revenue of $14.9 million, an increase of 72% compared to the prior year period Increased ...
-
iSTAR Medical Expands Commercial Rollout with First MINIject Surgeries in Switzerland
The only commercially available MIGS device currently targeting the supraciliary space now available to patients and surgeons in Switzerland First implantations performed by Prof. Dr Kaweh Mansouri at Swiss Visio, Clinique de Montchoisi, Lausanne and Prof. Dr med. Jan Darius Unterlauft at Inselspital, Bern WAVRE, Belgium — 10 May 2022: iSTAR Medical, a medtech company delivering ...
-
Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The conference will be held May 1-4, ...
By Eyevensys
-
Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Resultsgrafic lines 4 Sight Sciences
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients’ lives, today reported financial results for the quarter and year ended December 31, 2021. Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year ...
-
Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to ...
-
Sight Sciences Announces Appointment of Brenda Becker to Board of Directors
Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022. As part of her duties, Ms. Becker has joined the Nominating and Governance Committee. Ms. Becker has more than 40 years of ...
-
MediPrint™ Ophthalmics Announces Initial Series A Funding Success
SAN DIEGO–(BUSINESS WIRE) (March 15th, 2022) –Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on enhancing vision for life, announces the initial closing of a Series A round that exceeded $2.5 million, including from existing investors. There will be a subsequent close of this round, in Q2 2022, when the round is ...
-
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapy
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generationiLink™ therapy designed to treat keratoconus. ...
-
PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting
Melbourne, Australia – March 4, 2022 – PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you